Santhera has in-licensed omigapil for development and commercialization in CMD, and initiated a clinical development program with public–private partners. Omigapil has been granted orphan drug designation for CMD in Europe and the US.
Erb M, et al. J Pharmacol Exp Ther 2009; 331:787–795.
Erb M, et al. PLoS One 2012; 7:e36153.
Clinical Trials Identifier NCT01805024 (CALLISTO trial). Available here. Accessed December 2015.
Muscular Dystrophy Campaign UK: Congenital Muscular Dystrophies Fact Sheet. Available here.
Bönnemann CG, et al. Neuromuscul Disord 2014; 24:289–311.
Wang CH, et al. J Child Neurol 2010; 25:1559–1581.